查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423588

到 2030 年肿瘤伴同性诊断市场预测：按产品、技术、适应症、最终用户和地区进行的全球分析

Oncology Companion Diagnostic Market Forecasts to 2030 - Global Analysis By Product (Instrument, Consumables and Software), Technology, Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肿瘤伴同性诊断市场规模将达到 35 亿美元，预计到 2030 年将达到 94 亿美元，预测期内复合年增长率为 14.9%。

肿瘤学中的伴同性诊断是指专门设计用于帮助癌症患者选择最合适的治疗方法或治疗策略的诊断方法和测试。透过识别患者肿瘤中的特定生物标记、基因突变和分子特征，这些测试可以帮助医疗专业人员为个别患者量身定制治疗计划。这些诊断发现了预测患者对特定治疗的潜在反应的生物标记。

根据美国癌症协会2022年1月预测，到年终，美国将总合新增190万癌症病例。此外，患有慢性病的人是美国最常使用伴同性诊断的人，推动了市场的成长。

越来越重视标靶治疗和免疫治疗

标靶治疗和免疫疗法通常需要特定的生物标记或基因指纹来进行最佳患者选择。伴同性诊断对于识别这些预测生物标记至关重要，以便根据患者的分子特征选择最佳治疗药物。伴同性诊断有助于将有效的标靶治疗和免疫疗法更快推向市场。经过验证的诊断的可用性可透过增加监管机构和医疗保健专业人员对其功效的信心来支持这些治疗方法的商业性成功。

开发成本高且报销有限

由于伴同性诊断的开发成本较高，诊断公司可能会选择不进行研发。这可能导致缺乏创造力并延迟新的和增强的癌症诊断的发展。由于成本问题，医疗保健系统或付款人可能不愿意为伴同性诊断提供资金，这可能会延迟测试的采用。因此，临床采用可能会被推迟，进一步阻碍市场成长。

能够缩短临床试验时间

有效伴同性更有可能对特定药物产生反应的患者群体的伴随诊断可以简化临床试验。将具有特定生物标记或基因谱的患者纳入其中有助于更快地在临床试验中证明疗效，从而有可能缩短开发新药的时间。补充诊断使临床试验能够更准确地识别和参与最有可能从正在研究的治疗中受益的人。因此，密集的患者招募可以减少完成实验所需的时间和资源，进一步加快受试者招募速度，并为预测期内的市场成长创造广泛的机会。

监管挑战和严格的核准流程

由于严格的监管标准，伴同性诊断通常需要更长的开发时间和更高的开发成本。获得监管部门的批准需要进行广泛的临床前和临床验证研究，从而导致更长的开发时间和更高的成本。不同肿瘤类型或病患小组之间生物标记表达的差异可能会对验证和解释过程提出挑战，这可能导致缺乏监管核准。

COVID-19 的影响

医疗保健和其他医疗机构已重新分配人员和设备，以适应 COVID-19 患者的增加。非紧急患者和相关诊断测试的积压是由于肿瘤学优先事项的转变，过去将重点放在紧急或严重的癌症病例。随着卫生保健系统适应流行病的障碍，癌症的筛检、诊断和治疗逐渐得到改善。继续努力解决延期病例和诊断测试的积压问题，有助于肿瘤伴同性诊断市场的復苏。

次世代定序仪（NGS）领域预计在预测期内规模最大

由于次世代定序对患者肿瘤 DNA、RNA 和其他遗传资料的全面探索，下一代次世代定序(NGS) 领域预计将出现良好的成长。与传统的单基因测试相比，它透过同时识别与癌症相关的多个基因突变、改变和生物标记来提供更完整的情况。在选择合格的患者进行评估新标靶治疗和免疫疗法的临床试验时，基于次世代定序仪的伴同性诊断至关重要且受市场驱动。

预计白血病领域在预测期内的复合年增长率最高。

由于白血病是一种影响骨髓和血液的恶性，因此预计白血病领域在预测期内将出现最高的复合年增长率。白血病是肿瘤伴同性诊断市场的主要部分之一，因为它是一种影响骨髓和血液的恶性。在寻找合格的患者进行测试新型免疫疗法、标靶治疗或白血病联合治疗的临床试验时，伴同性发挥重要作用。伴同性诊断支持创新治疗方法和治疗方法的创建和评估。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。这是因为来自美国癌症研究所 (NCI) 等组织的资金加速了精准治疗的市场开拓，并对当地市场产生了积极影响。 NCI 的小型企业技术转移 (STTR) 和小型企业创新研究 (SBIR) 计划致力于增强和创建用于癌症诊断、预防和治疗的尖端工具和解决方案。此外，在加拿大举行的许多会议旨在提高人们对伴随诊断发展和趋势的认识，进一步支持了这种扩张。

复合年增长率最高的地区：

由于各种恶性的盛行率不断增加以及对准确和客製化诊断设备的需求不断增长，预计亚太地区在预测期内将呈现最高的复合年增长率。使用伴同性诊断识别生物标记有助于为特定患者量身定制治疗计划。患者和医疗保健提供者对伴同性诊断和个人化治疗的好处的了解不断增加，导致其采用率不断提高。此外，亚太国家不断上涨的医疗成本也促进了先进诊断技术的取得。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肿瘤伴同性诊断市场：依产品

  • 装置
  • 消耗品
  • 软体

第六章全球肿瘤伴同性诊断市场：依技术分类

  • 下一代定序（NGS）
  • 聚合酶炼式反应 (PCR)
  • 原位杂合反应(ISH)
  • 萤光原位杂合反应（FISH）
  • 免疫组织化学 (IHC)
  • 蛋白质表现分析
  • 基因突变分析
  • 基于微阵列的测定
  • 甲基化分析
  • 其他技术

第七章全球肿瘤伴同性诊断市场：依适应症分类

  • 白血病
  • 黑色素瘤
  • 摄护腺癌
  • 乳癌
  • 大肠直肠癌
  • 非小细胞肺癌
  • 卵巢癌
  • 脑肿瘤
  • 淋巴瘤
  • 其他适应症

第八章全球肿瘤伴同性诊断市场：依最终用户分类

  • 学术医疗中心
  • 医院
  • 病理/诊断实验室

第九章全球肿瘤伴同性诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Roche Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Abbott
  • Invivoscribe, Inc.
  • bioMerieux SA
  • Myriad Genetics, Inc.
  • ARUP Laboratories
  • QIAGEN NV
  • Agendia NV
  • Biogenex Laboratories, Inc.
  • GE Healthcare
  • Life Technologies Corporation
  • Ventana Medical Systems, Inc.
  • Labcorp Drug Development
  • Leica Biosystems
  • MolecularMD Corporation
  • Dako, Inc.
Product Code: SMRC24822

According to Stratistics MRC, the Global Oncology Companion Diagnostic Market is accounted for $3.5 billion in 2023 and is expected to reach $9.4 billion by 2030 growing at a CAGR of 14.9% during the forecast period. Companion diagnostics in oncology refers to diagnostic methods or tests that are intended specially to help cancer patients choose the best therapy or course of treatment. By identifying certain biomarkers, genetic mutations, or molecular features in a patient's tumour, these tests assist medical professionals in customizing treatment plans for individual patients. These diagnostics find biomarkers that predict a patient's potential response to a certain treatment.

According to the American Cancer Society, in January 2022, a total of 1.9 million new cancer cases from cancer are expected to occur in the United States by the end of 2022. Moreover, people with chronic conditions are the most frequent users of companion diagnostics in the United States; they drive the market's growth.

Market Dynamics:

Driver:

Growing emphasis on targeted therapies and immunotherapies

For the best patient selection, targeted treatments and immunotherapies frequently need for certain biomarkers or genetic fingerprints. In order to match patients with the most appropriate medicines based on their molecular profile, companion diagnostics are essential in the identification of these predictive biomarkers. Complementary diagnostics help effective targeted treatments and immunotherapies reach the market more quickly. The availability of validated diagnostics helps these therapies succeed commercially by boosting the trust of regulators and healthcare professionals in their effectiveness.

Restraint:

High development costs and limited reimbursement

Diagnostic firms may choose not to engage in research and development due to the high development costs involved with companion diagnostics. This can result in a lack of creativity and slow development of fresh, enhanced oncology diagnostic tests. Healthcare systems or payers may be reluctant to fund companion diagnostics owing to cost concerns, which might result in a delayed uptake of the tests. Their incorporation into clinical practice may be delayed as a result and further hamper the growth of the market.

Opportunity:

Its ability to reduce clinical trial timelines

Clinical trials can be streamlined by oncology companion diagnostics that effectively identify patient populations likely to react to a certain drug. Trials can prove efficacy faster by including patients with certain biomarkers or genetic profiles, which might shorten the time it takes to create new drugs. Complementary diagnostics enable clinical trials to more accurately identify and enlist people who will most likely benefit from the investigated treatment. Thus, the time and resources required to complete the experiment are decreased as a result of the focused patient recruiting, which speeds up enrolment further creating wide range of opportunities for the growth of the market during the forecast period.

Threat:

Regulatory challenges and stringent approval processes

Complying with strict regulatory criteria frequently results in longer development times and higher development costs for companion diagnostics. The necessity of conducting extensive preclinical and clinical validation studies in order to obtain regulatory clearance results in longer development times and higher costs. The presence of variability in biomarker expression among distinct tumour types or patient groups might provide challenges to the validation and interpretation process, which may result in regulatory approvals being denied.

Covid-19 Impact

Hospitals and other healthcare institutions reallocated personnel and equipment in order to handle the increase in COVID-19 patients. A backlog of non-urgent patients and accompanying diagnostic tests resulted from priorities shifting in oncology departments, which were centered on urgent or critical cancer cases. Cancer screenings, diagnoses, and treatments have gradually improved as healthcare systems have adjusted to the obstacles presented by the epidemic. Ongoing initiatives to clear the backlog of postponed cases and diagnostic testing have contributed to the market recovery for cancer companion diagnostics.

The next-generation sequencing (NGS) segment is expected to be the largest during the forecast period

The next-generation sequencing (NGS) segment is estimated to have a lucrative growth, because of comprehensive study of a patient's tumor DNA, RNA, and other genetic data which is made possible by next-generation sequencing. Comparing it to conventional single-gene testing, it allows for the simultaneous identification of several genetic mutations, changes, and biomarkers linked to cancer, yielding a more complete picture. When it comes to selecting patients who are qualified for clinical trials evaluating new targeted treatments or immunotherapies, next-generation sequencing -based companion diagnostics are essential thus propelling the market.

The leukemia segment is expected to have the highest CAGR during the forecast period

The leukemia segment is anticipated to witness the highest CAGR growth during the forecast period, as leukemia is a malignancy that affects the bone marrow and blood. It is one of the major segments of the oncology companion diagnostic market. As soon as it comes to finding qualified individuals for clinical trials testing novel immunotherapies, targeted therapies, or combination treatments for leukemia, companion diagnostics play a crucial role. They aid in the creation and assessment of innovative therapies and therapeutic approaches.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing funding from organizations like the National Cancer Institute (NCI) would hasten the development of precision therapies and have a favorable impact on the regional market. The NCI's Small Business Technology Transfer (STTR) and Small Business Innovation Research (SBIR) programs work to enhance and create cutting-edge tools and solutions for cancer diagnosis, prevention, and treatment. Furthermore, a number of conferences held in Canada to raise awareness of the developments and trends in CDx serve as an additional boost to this expansion.

Region with highest CAGR:

Asia-Pacific is projected to have the highest CAGR over the forecast period, owing to growing incidence of different malignancies has increased need for accurate and customized diagnostic instruments. The identification of biomarkers using companion diagnostics facilitates the customization of treatment plans for specific patients. Adoption has expanded as a result of patients' and healthcare professionals' growing understanding of the advantages of companion diagnostics and tailored treatment. Furthermore, access to sophisticated diagnostic technologies has been made easier by the growing cost of healthcare in a number of Asia Pacific nations.

Key players in the market

Some of the key players profiled in the Oncology Companion Diagnostic Market include Roche Ltd., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Illumina, Inc., Agilent Technologies, Inc., Abbott, Invivoscribe, Inc., bioMerieux SA, Myriad Genetics, Inc., ARUP Laboratories, QIAGEN N.V., Agendia N.V, Biogenex Laboratories, Inc., GE Healthcare, Life Technologies Corporation, Ventana Medical Systems, Inc., Labcorp Drug Development, Leica Biosystems, MolecularMD Corporation and Dako, Inc.

Key Developments:

In December 2023, Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes.

In November 2023, Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List. The tests complete Roche's panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.

In November 2023, Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences.

Products Covered:

  • Instrument
  • Consumables
  • Software

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Fluorescence In Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Protein Expression Analysis
  • Genetic Mutation Analysis
  • Microarray-Based Assays
  • Methylation Analysis
  • Other Technologies

Indications Covered:

  • Leukemia
  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Brain Tumors
  • Lymphoma
  • Other Indications

End Users Covered:

  • Academic Medical Center
  • Hospital
  • Pathology/Diagnostic Laboratory

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Oncology Companion Diagnostic Market, By Product

  • 5.1 Introduction
  • 5.2 Instrument
  • 5.3 Consumables
  • 5.4 Software

6 Global Oncology Companion Diagnostic Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 In Situ Hybridization (ISH)
  • 6.5 Fluorescence In Situ Hybridization (FISH)
  • 6.6 Immunohistochemistry (IHC)
  • 6.7 Protein Expression Analysis
  • 6.8 Genetic Mutation Analysis
  • 6.9 Microarray-Based Assays
  • 6.10 Methylation Analysis
  • 6.11 Other Technologies

7 Global Oncology Companion Diagnostic Market, By Indication

  • 7.1 Introduction
  • 7.2 Leukemia
  • 7.3 Melanoma
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Colorectal Cancer
  • 7.7 Non-Small Cell Lung Cancer
  • 7.8 Ovarian Cancer
  • 7.9 Brain Tumors
  • 7.10 Lymphoma
  • 7.11 Other Indications

8 Global Oncology Companion Diagnostic Market, By End User

  • 8.1 Introduction
  • 8.2 Academic Medical Center
  • 8.3 Hospital
  • 8.4 Pathology/Diagnostic Laboratory

9 Global Oncology Companion Diagnostic Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche Ltd.
  • 11.2 F. Hoffmann-La Roche Ltd.
  • 11.3 Thermo Fisher Scientific, Inc.
  • 11.4 Illumina, Inc.
  • 11.5 Agilent Technologies, Inc.
  • 11.6 Abbott
  • 11.7 Invivoscribe, Inc.
  • 11.8 bioMerieux SA
  • 11.9 Myriad Genetics, Inc.
  • 11.10 ARUP Laboratories
  • 11.11 QIAGEN N.V.
  • 11.12 Agendia N.V
  • 11.13 Biogenex Laboratories, Inc.
  • 11.14 GE Healthcare
  • 11.15 Life Technologies Corporation
  • 11.16 Ventana Medical Systems, Inc.
  • 11.17 Labcorp Drug Development
  • 11.18 Leica Biosystems
  • 11.19 MolecularMD Corporation
  • 11.20 Dako, Inc.

List of Tables

  • Table 1 Global Oncology Companion Diagnostic Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Oncology Companion Diagnostic Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Oncology Companion Diagnostic Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 4 Global Oncology Companion Diagnostic Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 5 Global Oncology Companion Diagnostic Market Outlook, By Software (2021-2030) ($MN)
  • Table 6 Global Oncology Companion Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 7 Global Oncology Companion Diagnostic Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 8 Global Oncology Companion Diagnostic Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 9 Global Oncology Companion Diagnostic Market Outlook, By In Situ Hybridization (ISH) (2021-2030) ($MN)
  • Table 10 Global Oncology Companion Diagnostic Market Outlook, By Fluorescence In Situ Hybridization (FISH) (2021-2030) ($MN)
  • Table 11 Global Oncology Companion Diagnostic Market Outlook, By Immunohistochemistry (IHC) (2021-2030) ($MN)
  • Table 12 Global Oncology Companion Diagnostic Market Outlook, By Protein Expression Analysis (2021-2030) ($MN)
  • Table 13 Global Oncology Companion Diagnostic Market Outlook, By Genetic Mutation Analysis (2021-2030) ($MN)
  • Table 14 Global Oncology Companion Diagnostic Market Outlook, By Microarray-Based Assays (2021-2030) ($MN)
  • Table 15 Global Oncology Companion Diagnostic Market Outlook, By Methylation Analysis (2021-2030) ($MN)
  • Table 16 Global Oncology Companion Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 17 Global Oncology Companion Diagnostic Market Outlook, By Indication (2021-2030) ($MN)
  • Table 18 Global Oncology Companion Diagnostic Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 19 Global Oncology Companion Diagnostic Market Outlook, By Melanoma (2021-2030) ($MN)
  • Table 20 Global Oncology Companion Diagnostic Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 21 Global Oncology Companion Diagnostic Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 22 Global Oncology Companion Diagnostic Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 23 Global Oncology Companion Diagnostic Market Outlook, By Non-Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 24 Global Oncology Companion Diagnostic Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 25 Global Oncology Companion Diagnostic Market Outlook, By Brain Tumors (2021-2030) ($MN)
  • Table 26 Global Oncology Companion Diagnostic Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 27 Global Oncology Companion Diagnostic Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 28 Global Oncology Companion Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Oncology Companion Diagnostic Market Outlook, By Academic Medical Center (2021-2030) ($MN)
  • Table 30 Global Oncology Companion Diagnostic Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 31 Global Oncology Companion Diagnostic Market Outlook, By Pathology/Diagnostic Laboratory (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.